Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y2I6
UPID:
NINL_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y2I6; A6NJN0; B3V9H6; B7Z1V8; Q5JYP0; Q8NE38; Q9NQE3
Background:
The Ninein-like protein plays a crucial role in microtubule organization within interphase cells, impacting cellular processes such as Golgi fragmentation and lysosome dispersion. Its overexpression affects mitotic spindle assembly, hinting at its importance in cell division and structural integrity.
Therapeutic significance:
Understanding the role of Ninein-like protein could open doors to potential therapeutic strategies, especially considering its implication in ovarian carcinogenesis. Its involvement in key cellular processes makes it a promising target for drug discovery efforts aimed at cancer treatment.